Related Experiment Video
Updated: Oct 26, 2025
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
A pancreas tumor derived organoid study: from drug screen to precision medicine
Jia Yao1, Man Yang2, Lawrence Atteh2
1Key Laboratory of Biological Therapy and Regenerative Medicine Transformation of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) one of the deadliest malignant tumor. Despite considerable progress in pancreatic cancer treatment in the past 10 years, PDAC mortality has shown no appreciable change, and systemic therapies for PDAC generally lack efficacy. Thus, developing biomarkers for treatment guidance is urgently required. This review focuses on pancreatic tumor organoids (PTOs), which can mimic the characteristics of the original tumor in vitro. As a powerful tool with several applications, PTOs represent a new strategy for targeted therapy in pancreatic cancer and contribute to the advancement of the field of personalized medicine.
Insights
Pancreatic tumor organoids (PTOs) offer a new approach to pancreatic cancer treatment. These models mimic tumors in vitro, aiding in personalized medicine and targeted therapy development for pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Oncology
- Biotechnology
- Personalized Medicine
Background:
- Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy with limited treatment efficacy.
- Despite advances, PDAC mortality rates have not significantly decreased, highlighting the need for novel therapeutic strategies.
- Current systemic therapies for PDAC often lack sufficient effectiveness, underscoring the urgent requirement for treatment guidance biomarkers.
Purpose of the Study:
- To review the application of pancreatic tumor organoids (PTOs) as a promising tool in pancreatic cancer research.
- To highlight PTOs' potential in advancing targeted therapy and personalized medicine for PDAC.
- To discuss how PTOs can overcome limitations of current treatment approaches.
Main Methods:
- This review focuses on pancreatic tumor organoids (PTOs) as a model system.
- The review synthesizes current research on PTOs' ability to mimic patient-specific tumor characteristics in vitro.
- Applications of PTOs in drug screening and personalized treatment strategies are discussed.
Main Results:
- Pancreatic tumor organoids (PTOs) accurately recapitulate the heterogeneity and complexity of the original tumor in vitro.
- PTOs serve as a valuable platform for preclinical drug testing and biomarker discovery.
- The use of PTOs demonstrates significant potential for guiding personalized treatment decisions in PDAC.
Conclusions:
- Pancreatic tumor organoids (PTOs) represent a significant advancement in cancer research, offering a faithful in vitro model of PDAC.
- PTOs are crucial for developing effective targeted therapies and advancing personalized medicine in pancreatic cancer.
- The integration of PTOs into clinical practice is expected to improve treatment outcomes for patients with pancreatic ductal adenocarcinoma.
